Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma

Area of Science:

• Immunology
• Allergic Inflammation Research
• Therapeutic Target Identification

Background:

• The CD86-CD28 pathway is crucial for T cell activation in allergic inflammation.
• Its role in the effector phase of allergic responses requires further elucidation.
• Investigating CD86's contribution to Th2 cell reactivation is essential.

Purpose of the Study:

• To determine the role of CD86 on dendritic cells in the reactivation of allergen-specific Th2 cells.
• To assess the impact of CD86 downregulation on Th2 cytokine production and asthma phenotypes.
• To evaluate the therapeutic potential of targeting CD86 in allergic asthma.

Main Methods:

• Utilized short interfering RNAs (siRNAs) to downregulate CD86 expression in vitro and in vivo.
• Examined the effects on dendritic cell activation of T cells.
• Assessed asthma phenotypes in a mouse model involving ovalbumin sensitization and challenge.

Main Results:

• CD86 siRNA treatment attenuated CD86 upregulation and impaired dendritic cell activation of T cells.
• Intratracheal CD86 siRNA administration reduced airway CD86 expression.
• Therapeutic intervention ameliorated airway eosinophilia, hyperresponsiveness, IgE, IL-5, IL-13, and CCL17 levels.

Conclusions:

• Local administration of CD86 siRNA during the effector phase effectively ameliorates asthma phenotypes.
• Targeting airway dendritic cells via siRNA suppresses airway inflammation and hyperresponsiveness.
• CD86 represents a promising therapeutic target for allergic asthma.